Surv BioPharma Inc.


Company Outline & Business Model

Company Outline

Company name Surv BioPharma Inc.
President Masaki Yamada

【Head Office & Research Laboratories】
Graduate School of Medical & Dental Sciences, Kagoshima University
8-35-1, Sakuragaoka, Kagoshima, 890-8544 Japan

【Tokyo Office】
Nihonbashi Life Science Building 2, 8F 
3-11-5, Nihonbashi Honcho, Chuo-ku, Tokyo 103-0023, Japan

TEL 【Head Office】+81(0)99-296-8110 【Tokyo Office】+81(0)3-6824-2310
E-mail info(at) ※convert (at) into@
Website URL
Established August 22, 2022
Capital JPY350,500,000 (including capital reserve)
Employees 11 (including Directors)
Core business Development & marketing of pharmaceutical products

Our Business Model

Our pharmaceutical business comprises the in-licensing drug candidates, developed on technologies pioneered by Kagoshima University, under licensing agreements or joint research agreements, and the primarily in-house nonclinical studies and early-stage clinical development of these drug candidates.

After establishing proof-of-concept (POC) (i.e., demonstrating an investigational drug’s efficacy when administered to patients) of our drug candidates as an initial indicator of their commercial value, we will build a revenue model consisting of lump-sum and milestone payments and post-marketing royalty payments through out-licensing to major pharmaceutical companies. These pharmas will then conduct Phase III (P3) studies typically on a cost scale of several tens of billion yen, and will subsequently market the approved drug products.

Through these business activities, Surv BioPharma will create a business structure with sustained and stable profitability, and will contribute to delivering the innovative seed technologies pioneered by Kagoshima University to society.

We will fulfill our corporate social responsibility as a drug discovery venture company originating from Kagoshima University by delivering new therapeutic drugs to patients via major pharmaceutical companies.